In Australia the government must balance access to new drugs against the cost to the Pharmaceutical Benefits Scheme. Economic evaluations can be used to ensure health resources are allocated efficiently, maximising patient outcomes for every dollar spent.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: